Clinical Trials for Kidney Cancer

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresected, metastatic or node-positive RCC (IMDC intermediate/poor risk) receiving standard first-line immunotherapy (IO-IO or IO-VEGF regimens) are randomized to immunotherapy alone versus the same therapy plus stereotactic ablative radiotherapy (SABR) to the intact primary kidney tumor. Regimens may include nivolumab + ipilimumab (PD-1 + CTLA-4), pembrolizumab or nivolumab combinations with VEGF/VEGFR TKIs (axitinib, lenvatinib, cabozantinib), or avelumab + axitinib.

ClinicalTrials.gov ID: NCT05327686

A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with functioning kidney transplants and unresectable or metastatic cutaneous melanoma (non-uveal), cSCC, BCC, or Merkel cell carcinoma receive nivolumab (PD‑1 inhibitor) plus ipilimumab (CTLA‑4 inhibitor) with concurrent sirolimus (mTOR inhibitor) and prednisone, followed by nivolumab maintenance. Designed to balance antitumor activity with graft preservation; prior PD-(L)1 exposure allowed, with re-induction permitted at progression.

ClinicalTrials.gov ID: NCT05896839

A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with multiple myeloma and significant renal impairment (eGFR <45) receive cyclophosphamide plus low-dose total body irradiation for lymphodepletion instead of fludarabine, followed by ciltacabtagene autoleucel (BCMA-directed CAR T with dual BCMA-binding domains). The study assesses safety/feasibility of this TBI-based approach and its impact on CAR T expansion and antimyeloma activity.

ClinicalTrials.gov ID: NCT06623630

Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Newly diagnosed multiple myeloma patients with significant renal impairment (CrCl <60 mL/min and/or dialysis) receive four 28-day cycles of subcutaneous daratumumab-hyaluronidase (anti‑CD38) plus bortezomib, cyclophosphamide, and dexamethasone, with outcomes focused on depth of hematologic response and renal recovery. Planned enrichment for approximately 50% African American participants; post-induction therapy follows standard practice (ASCT if eligible or additional Dara-CyBorD, then maintenance with lenalidomide plus SC daratumumab).

ClinicalTrials.gov ID: NCT06142396

A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adolescents and adults with advanced measurable HLRCC-associated RCC or sporadic/non-HLRCC papillary RCC (prior VEGF therapy allowed, but no prior bevacizumab or PD-1/PD-L1 in the advanced setting), including patients with treated/stable brain mets. Treatment combines bevacizumab (anti-VEGF), erlotinib (EGFR TKI), and atezolizumab (anti–PD-L1) given in 21-day cycles until progression/toxicity, aiming to improve response and disease control.

ClinicalTrials.gov ID: NCT04981509

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with MGRS due to plasma cell dyscrasia, including NDMM with cast nephropathy or other biopsy-proven MGRS lesions (excluding AL amyloidosis), impaired renal function/proteinuria, and no prior anti–plasma cell therapy receive CyBorD plus subcutaneous daratumumab. Daratumumab is an anti‑CD38 monoclonal antibody; treatment includes 8 induction cycles with optional ASCT and, if ineligible, maintenance bortezomib/dexamethasone every other week plus daratumumab every 4 weeks.

ClinicalTrials.gov ID: NCT06083922

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic RCC and at least one measurable untreated or locally progressive brain metastasis (asymptomatic/mildly symptomatic, largely steroid-independent; ECOG 0–2) receive nivolumab (PD‑1 inhibitor) plus ipilimumab (CTLA‑4 inhibitor) with cabozantinib (MET/VEGFR/AXL TKI), with maintenance nivolumab/cabozantinib; prior systemic therapy allowed if no prior CTLA‑4, cabozantinib, or MET inhibitor. Primary aim is to improve intracranial PFS; a safety lead-in may omit ipilimumab if excess toxicity.

ClinicalTrials.gov ID: NCT05048212

A Phase 1b Study to Assess the Effects of Belzutifan on 89Zr-DFO-girentuximab Uptake as a Surrogate to Determine CAIX Tumor Expression in Patients With Clear Cell Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with advanced/metastatic clear cell RCC after progression on prior immune checkpoint therapy (≥2 prior regimens) receive belzutifan monotherapy (HIF‑2α inhibitor) with paired 89Zr‑DFO‑girentuximab PET imaging to assess changes in CAIX expression at 4 weeks. Includes patients with measurable disease, KPS ≥60%, and allows controlled viral infections and stable brain metastases.

ClinicalTrials.gov ID: NCT07179770

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For pediatric and young adult patients with relapsed/refractory non-CNS solid tumors confirmed to express glypican-3 (including hepatocellular carcinoma meeting Barcelona stage A–C and Child-Pugh <7), this study tests autologous GPC3-targeted CAR T cells “armored” with IL-15 and IL-21 to enhance expansion/persistence. Patients receive cyclophosphamide/fludarabine lymphodepletion followed by a single IV infusion of SC-CAR.GPC3xIL15.21 with dose escalation, with an inducible caspase-9 safety switch that can be activated using rimiducid for severe toxicity.

ClinicalTrials.gov ID: NCT07148050

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally confirmed IDH1 R132–mutated hematologic malignancies (including AML and MDS) or non-glioma solid tumors who have moderate/severe hepatic impairment or severe renal impairment (with matched adequate-function control cohorts) receive once-daily oral ivosidenib, a mutant IDH1 inhibitor that lowers 2-hydroxyglutarate and promotes differentiation. Azacitidine co-treatment is allowed for hematologic malignancies, and prior/ongoing ivosidenib may be permitted in select cases.

ClinicalTrials.gov ID: NCT07006688